Description
Novartis AG (NVS): Acquisition of Mariana Oncology for Expansion of Oncology Portfolio
Novartis’s second quarter 2024 earnings were decent and revealed a company strongly positioned and confident of its continued growth trajectory. From a financial standpoint, the Swiss multinational pharmaceutical firm posted a solid performance with 11% quarter-on-quarter growth in sales, profits expanding 19%, and a core margin of 39.6%. The robustness in financials was driven by commendable productivity as well as sustained sales growth.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
